文章引用说明 更多>> (返回到该文章)

L. H. Butterfield, A. Ribas, D. M. Potter and J. S. Economou. Spontaneous and vaccine induced AFP-specific T cell phenol- types in Subjects with AFP-positive hepatocellular cancer. Can- cer Immunol. Immunother, 2007, 56: 1931-1943.

被以下文章引用:

  • 标题: AFP特异性肝癌疫苗抑制肝细胞癌生长AFP Specific Liver Tumor Vaccines Inhibit Hepatocellular Carcinoma Growth

    作者: 刘扬, 王跃如, Lisa HButterfield

    关键字: 甲胎蛋白, 树突状细胞, 细胞因子, AFP特异性T细胞Alpha-Fetoprotein (AFP); Dendritic Cell; Cytokine; AFP-Specific T Cells

    期刊名称: 《Hans Journal of Surgery》, Vol.1 No.3, 2012-10-31

    摘要: 目的:甲胎蛋白作为一种肿瘤特异性抗原,是临床上诊断肝癌的重要指标。本研究中,我们检测了AFP特异性T细胞的体外抗肿瘤免疫活性。方法:我们采用经过AFP抗原决定簇肽刺激或慢病毒转染的树突状细胞(dendritic cells, DC),活化AFP特异性的CD4+T细胞和CD8+T细胞(肝癌疫苗),并在体外检测了这群T细胞对人肝癌细胞HepG2的杀伤活性。结果:本研究结果显示,AFP特异性的CD4+T细胞和CD8+T细胞体外能有效杀伤HepG2细胞,上调培养体系中IL-2、IFN-γ、TNF-α、穿孔素、颗粒酶的水平,对于T细胞活化的负调控因子IL-10,具有显著的抑制作用。结论:经DC活化后的AFP特异性T细胞具有显著的体外抗肿瘤免疫活性,为肝细胞癌的临床免疫治疗提供了依据。 Objective: Alpha-fetoprotein (AFP), a tumor-associated antigen for hepatocellular carcinoma (HCC), is an established biomarker for hepatocellular cancer (HCC). In this study, we detected antitumor activity of AFP specific T cells in vitro. Methods: We created a lentivirus expressing AFP (Lenti-AFP) and investigated the antitumor activity of AFP-specific CD4+ and CD8+ T cells(liver tumor vaccines), which were activated by either AFP peptide-pulsed or Lenti-AFP-engineered DC in vitro. Results: Our research demonstrated that the AFP-specific T cells could efficiently kill HepG2 cells, by significantly increasing the level of IL-2, IFN-γ、TNF-α、perforin and granzyme B, as well as by inhibiting the production of IL-10 (a negative regulator of T cell activation). Conclusion: AFP-specific CD4+ and CD8+ T cells (liver tumor vaccines) which were activated by either AFP peptide-pulsed or Lenti-AFP-engineered DC have obviously antitumor activity. This study provides new insight into the design of DC activated antigen-specific T cell-based clinical trials

在线客服:
对外合作:
联系方式:400-6379-560
投诉建议:feedback@hanspub.org
客服号

人工客服,优惠资讯,稿件咨询
公众号

科技前沿与学术知识分享